Sage Therapeutics announces FDA approval of ZULRESSO™ (brexanolone) injection
Sage Therapeutics announced the FDA has approved ZULRESSOTM (brexanolone) injection for the treatment of postpartum depression. ZULRESSO is the first and only medicine specifically approved to treat PPD, the most common medical complication of childbirth. March 19, 2019